About WUXI XDC Company

The Group is a leading CRDMO focusing on the global ADC and broader bioconjugate drug markets, and is also a company dedicated to providing comprehensive integrated services. With expertise in biopharmaceuticals and small molecule drugs, the Group provides comprehensive interdisciplinary services covering the discovery, research, development and manufacture of bioconjugated drugs. The Group has set up dedicated laboratories and production facilities located nearby to provide such services, which may greatly reduce development time and costs. According to Frost & Sullivan data, the Group is the world's second-largest ADC and other bioconjugated drug CRDMO in terms of earnings in 2022. The Group is committed to continuously enhancing the platform to drive and transform the development of the bioconjugated medicine industry, empowering global biopharmaceutical partners and benefiting patients around the world. With a comprehensive one-stop bioconjugated drug platform covering key aspects of bioconjugated drug CRDMO services, including discovery, process development and GMP production of bioconjugated drugs, mAb intermediates, and bioconjugated drug-related connectors and payloads, the Group empowers customers to advance their projects at any stage of the development process. During the reporting period, the Group's services were based on the strategy of “empowering, following and winning molecules” to continuously meet the needs of customers/partners to develop bioconjugated drugs. The Group adopts the “Empower, Follow, and Win Molecules” strategy to not only serve customers from the early stages of the product development cycle, grow with existing customers, but also win new customers from the bioconjugated drug process. Due to quality of service, industry-leading development schedules, world-class and innovative process development technology, and proven GMP production capacity, the Group has been able to achieve high customer retention rates. Since the Group was founded in 2013 and until June 30, 2024, almost all of its customers who have advanced bioconjugated drug candidates to the development stage of bioconjugated drug discovery or overall projects have continued to cooperate with us. Acquiring customers at the CMC stage is another key driver of the Group's future growth.